Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus gemcitabine/cisplatin neoadjuvant therapy for high-risk locally advanced nasopharyngeal carcinoma
ChiCTR2200056941Phase 4Completed
- Sponsor
- Jiangmen Central Hospital
- Start
- Feb 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab, gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by Jiangmen Central Hospital. Primary endpoint: Complete response rate after neoadjuvant treatment. Started Feb 2022; status: completed.
02
Drugs
tislelizumabgemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2200056941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056941.